| 1.35 0.01 (0.75%) | 08-19 10:31 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.78 | 1-year : | 2.08 |
| Resists | First : | 1.52 | Second : | 1.78 |
| Pivot price | 1.3 |
|||
| Supports | First : | 1.28 | Second : | 1.12 |
| MAs | MA(5) : | 1.23 |
MA(20) : | 1.33 |
| MA(100) : | 1.55 |
MA(250) : | 1.55 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 36.5 |
D(3) : | 23.4 |
| RSI | RSI(14): 49.2 |
|||
| 52-week | High : | 2.61 | Low : | 1.05 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CHRS ] has closed below upper band by 43.9%. Bollinger Bands are 44.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.36 - 1.37 | 1.37 - 1.38 |
| Low: | 1.2 - 1.21 | 1.21 - 1.22 |
| Close: | 1.33 - 1.34 | 1.34 - 1.35 |
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.
Mon, 17 Aug 2026
Coherus Oncology Announces Special Dividend of Contingent Value Rights Tied to Legacy Biosimilar Asset Sales - Quiver Quantitative
Mon, 17 Aug 2026
Coherus will give eligible holders rights to cash from former assets—but they may expire unpaid - Stock Titan
Wed, 12 Aug 2026
Coherus Oncology (CHRS) Q2 2026 Earnings Call Transcript - The Globe and Mail
Wed, 05 Aug 2026
Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
Wed, 05 Aug 2026
Coherus Oncology (NASDAQ: CHRS) posts Q2 2026 loss amid growing LOQTORZI revenue - Stock Titan
Wed, 05 Aug 2026
Coherus Oncology (NASDAQ:CHRS) Announces Quarterly Earnings Results - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 155 (M) |
| Shares Float | 136 (M) |
| Held by Insiders | 19.1 (%) |
| Held by Institutions | 39.6 (%) |
| Shares Short | 23,890 (K) |
| Shares Short P.Month | 25,640 (K) |
| EPS | -1.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.38 |
| Profit Margin | -259.5 % |
| Operating Margin | -226 % |
| Return on Assets (ttm) | -30.6 % |
| Return on Equity (ttm) | -178.4 % |
| Qtrly Rev. Growth | 39.5 % |
| Gross Profit (p.s.) | 0.22 |
| Sales Per Share | 0.32 |
| EBITDA (p.s.) | -0.98 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -186 (M) |
| Levered Free Cash Flow | -154 (M) |
| PE Ratio | -1.08 |
| PEG Ratio | 0 |
| Price to Book value | 3.41 |
| Price to Sales | 4.04 |
| Price to Cash Flow | -1.11 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|